CTOs on the Move

Proclara Biosciences

www.proclarabio.com

 
Proclara is pioneering a new approach to treating neurodegenerative diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by Alzheimer`s, Parkinson`s, and other diseases caused by protein misfolding. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Proclara Biosciences raised $47M on 09/07/2016

Similar Companies

Novaseek Research

Novaseek is transforming how biomedical researchers access real-world hospital patient data and human biospecimens. Researchers rely on Novaseek to plan projects, and procure high quality biospecimens and clinical data needed to power discovery. Increasing productivity and de-risking projects across R&D enterprise begins with NovaSeek!

Advanced Vision Therapies

Advanced Vision Therapies is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Virtual Incision

Virtual Incision Corporation is a privately-held medical device company focused on developing an advanced, miniaturized robot for general surgery abdominal procedures, such as colon resections. Propelled by the knowledge that colorectal and lower gastrointestinal procedures are the fastest growing in the United States, Dr. Dmitry Oleynikov and Dr. Shane Farritor founded Virtual Incision in 2006. The company is a spin-out of the University of Nebraska, where Dr. Dmitry Oleynikov and Dr. Shane Farritor are currently based. John Murphy joined Virtual Incision in 2012 and is based in Pleasanton, California.

Scribe Therapeutics

Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.

Inform Genomics

Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development--OnPART™ and HSCT/Mucositis™--designed not only to predict a patient's risk for developing common chemotherapy-related side effects, but also to assess a patient's willingness to tolerate those side effects. The Company's novel, IP-protected technology platform capitalizes on big data storage/memory and sophisticated cloud computing technologies. It consists of proprietary Bayesian networks and other advanced bioinformatic analytics combined with validated patient assessment tools. The Company's analytics discover interactions of genes and single nucleotide polymorphisms (SNPs) that can predict clinical outcomes. Inform Genomics' goal is to be a trusted partner to health care practitioners so that they, together with their patients, can make optimal health care choices based on an individual patient's needs and values.